Ma Chao, Ma Rui-Jie, Hu Kang, Zheng Qi-Ming, Wang Ye-Peng, Zhang Nan, Sun Zhi-Gang
Department of Thoracic Surgery, Central Hospital Affiliated to Shandong First Medical University, 105 Jiefang Road, Jinan, 250013, Shandong, China.
School of Clinical Medicine, Weifang Medical University, Weifang, 261053, Shangdong, China.
Cancer Cell Int. 2022 Mar 24;22(1):133. doi: 10.1186/s12935-022-02539-5.
Lung cancer remains one of the major causes of cancer-related death globally. Recent studies have shown that aberrant mA levels caused by METTL3 are involved in the malignant progression of various tumors, including lung cancer. The mA modification, the most abundant RNA chemical modification, regulates RNA stabilization, splicing, translation, decay, and nuclear export. The methyltransferase complex plays a key role in the occurrence and development of many tumors by installing mA modification. In this complex, METTL3 is the first identified methyltransferase, which is also the major catalytic enzyme. Recent findings have revealed that METTL3 is remarkably associated with different aspects of lung cancer progression, influencing the prognosis of patients. In this review, we will focus on the underlying mechanism of METT3 in lung cancer and predict the future work and potential clinical application of targeting METTL3 for lung cancer therapy.
肺癌仍然是全球癌症相关死亡的主要原因之一。最近的研究表明，由METTL3引起的异常mA水平参与了包括肺癌在内的各种肿瘤的恶性进展。mA修饰是最丰富的RNA化学修饰，可调节RNA的稳定性、剪接、翻译、降解和核输出。甲基转移酶复合物通过安装mA修饰在许多肿瘤的发生和发展中起关键作用。在这个复合物中，METTL3是第一个被鉴定的甲基转移酶，也是主要的催化酶。最近的研究结果表明，METTL3与肺癌进展的不同方面显著相关，影响患者的预后。在这篇综述中，我们将重点关注METT3在肺癌中的潜在机制，并预测靶向METTL3用于肺癌治疗的未来工作和潜在临床应用。
